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ABSTRACT 
 
Gene knock-out studies in acute experimental stroke suggest that nitric oxide (NO) produced by the 
neuronal or inducible isoforms of nitric oxide synthase (nNOS, iNOS) is detrimental, whilst that 
derived from the endothelial isoform (eNOS) is beneficial. However, experimental studies with 
nitric oxide synthase inhibitors (NOS inhibitors) have given conflicting results. 
 
Published controlled studies of NOS inhibitors in experimental stroke were identified from 
EMBASE, PubMed and reference lists. Data on the effect of NOS inhibition on lesion volume 
(mm
3
, %) and cerebral blood flow (CBF, %, ml.min
-1
.g
-1
) were extracted and analysed using the 
Cochrane Review Manager software. 
 
72 studies were identified. NOS inhibitors reduced total infarct volume in permanent (standardised 
mean difference, SMD -0.51, 95% confidence intervals, 95% CI -0.82, -0.20) and transient (SMD -
1.01, 95% CI –1.29, -0.73) experimental stroke. Similar reductions in lesion volume were present in 
cortical and sub-cortical areas in both models. Cortical CBF was reduced in permanent (SMD -0.80, 
95% CI –1.34, -0.27) but not transient stroke. When assessed by type of inhibitor, total lesion 
volume was reduced in permanent models by nNOS (SMD -1.36, 95% CI -0.67, -2.05) and iNOS 
(SMD -0.92, 95% CI –1.16, -0.69) inhibitors, but not by non-selective inhibitors. All types of NOS 
inhibitors reduced infarct volume in transient models. 
 
Selective inhibitors of nNOS and iNOS appear to reduce lesion volume in both permanent and 
transient models of cerebral ischaemia. The lack of effect on lesion size by non-selective inhibitors 
could reflect co-inhibition of eNOS. NOS inhibition may have negative effects on CBF but further 
studies are required. Selective nNOS and iNOS inhibitors are candidate treatments for acute 
ischaemic stroke. 
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INTRODUCTION 
 
Nitric oxide (NO) is synthesised from its precursor L-arginine by the action of nitric oxide synthase 
(NOS). NO is produced in the brain following the onset of cerebral ischaemia (Malinski et al 1993), 
although its precise role in the pathophysiology of stroke is unclear. Gene knockout studies have 
determined that NO derived from the endothelial isoform of NOS (eNOS) is beneficial in acute 
stroke (Huang et al. 1996). This may be due, in part, to antiplatelet effects (Welch and Loscalzo 
1994) and preservation of cerebral blood flow (Iadecola et al. 1994). In contrast, NO produced by 
the neuronal and inducible isoforms of NOS (nNOS, iNOS) can be neurotoxic (Huang et al. 1994; 
Zhao et al. 2000). This probably occurs through NO induced formation of peroxynitrite (Beckman 
et al. 1990) and toxic free radicals leading to damage by lipid peroxidation (Radi et al. 1991). NO 
further potentiates damage by inhibiting enzymes needed for mitochondrial respiration (respiratory 
chain complex 1 and 2), glycolysis (GAPDH) and DNA replication (ribonucleotide reductase) 
(Dawson et al. 1992b; Dimmeler and Brune 1993; Garthwaite 1991; Nathan 1992). Moreover, NO 
has been reported to stimulate the release of the neurotransmitter glutamate and could contribute to 
excitotoxicity (Montague et al. 1994; Sorkin 1993). Consequently, inhibition of NO production has 
been considered to be a candidate treatment for acute stroke. 
 
The first NOS inhibitors were the guanidino aminoacids, many of which act competitively at the 
NOS active site.  Examples include, N
G
-nitro-L-arginine (L-NNA), N
G
-nitro-L-arginine methyl 
ester (L-NAME, a methyl ester pro-drug that is activated to become L-NNA) and N
G
-monomethyl-
L-arginine (L-NMMA). Both L-NAME and L-NNA exhibit greater in-vitro potency than L-NMMA 
in inhibiting nNOS and eNOS versus iNOS. However, none of the guanidino aminoacids 
discriminate sufficiently to enable them to be used to target a single NOS isoform. By contrast, 
some inhibitors possess higher affinity against one isoform and are commonly referred to as 
‘selective’, although this term is used rather indiscriminately (Alderton et al. 2001). Agents that are 
used to target iNOS include: aminoguanidine, N
G
-iminoethyl-L-lysine (L-NIL), N
G
-iminoethyl-L-
ornithine (L-NIO), the bis-isothioureas (PBITU) (Garvey et al. 1994), 1400W (N-[3-
(aminomethyl)benzyl]acetamidine), GW273629 and GW274150 (Young et al. 2000). Other agents 
are used to target nNOS and include: 7-nitroindinazole (7-NI), tri(fluoromethylphenyl)imidazole 
(TRIM) (Handy et al. 1995), ARL 17477, AR-R18512 (Reif et al. 2000), BN 80933 (Chabrier et al. 
1999), S-ethyl and S-methyl thiocitrulline and vinyl L-NIO. Recent in-vitro studies have suggested 
that in some cases the distinction between selective iNOS and selective nNOS inhibitor may not be 
straightforward. For example, aminoguanidine is only mildly selective against nNOS in-vitro (~5 
fold) and probably affects other molecular targets (Alderton et al. 2001). Similarly, 7-NI has been 
found to be an equipotent inhibitor of all three isoforms of NOS at the isolated enzyme level 
(Alderton et al. 2001; Escott et al. 1998) although it has more selectivity for nNOS in vivo, possibly 
a consequence of cell specific effects (neuronal verses endothelial) (Alderton et al. 2001).  
 
Pre-clinical studies of all of these agents have given variable results for effects on lesion size and 
cerebral blood flow (CBF) in animal models of cerebral ischaemia (Willmot and Bath 2003). 
Hence, the aim of the present investigation was to determine systematically what effect NOS 
inhibitors have on these parameters. 
METHODS 
 
Study identification 
Experimental studies assessing the effects of NOS inhibitors on stroke lesion volume and cerebral 
blood flow (CBF) in ischaemic stroke models (transient or permanent, global or focal, any species) 
were identified. Searches were made of ‘EMBASE’ and ‘Pubmed’ by MW for articles published 
from 1980 - 2002. For the EMBASE search four primary keywords (nitric oxide, brain, ischaemia, 
non-human) were chosen combined with a fifth chosen from a list of NOS inhibitors. Different 
primary keywords were used in the Pubmed search (nitric oxide, cerebro*, ischaemia) which was 
then limited to animal studies. Other publications were found from reference lists and review 
articles by CG, SM and PB. Abstracts were then used to select relevant articles for an examination 
of the full publication by MW. Final decisions on inclusion or exclusion were made by MW and 
PB. Articles were excluded for several reasons, namely: not a stroke model, NOS inhibitor not 
administered, outcomes other than infarct volume or CBF, no control group, insufficient other data 
given, or duplicate publication. 
 
Data Extraction 
Infarct volume data (mm
3
 or % of normal brain) and CBF data (ml.min
-1
.g
-1
 or % of baseline 
readings or baseline control) were extracted for analysis. Infarct volume measurements from the 
longest period of follow-up were used. CBF measurements after one hour of occlusion or 
reperfusion were used in permanent and transient stroke respectively. Where possible, regional 
infarct volume and CBF data were obtained separately for total brain, cortex and sub-cortex. In 
cases where region was not specified then the measurements were classified as total brain. If an 
article investigated dose response relationships or optimal timing of administration then data from 
each individual experimental condition were included separately. In cases where the number of 
animals in each experiment was given as a range then it was assumed to be the lowest figure. 
Where numerical values were not available, data were estimated directly from enlarged graphs 
using a ruler. All data extraction was done by two independent authors (MW, CG); discrepancies 
were resolved by PB. Finally, the methodological quality of the included articles was assessed on 
an 8 point scale (Horn et al. 2001) based on published recommendations for investigating new 
agents in experimental stroke (Stroke Therapy Academic Industry Roundtable (STAIR) 1999); one 
point was given for written evidence of each of the following factors; (i) randomisation; (ii) 
monitoring of physiological parameters; (iii) assessment of dose response relationship; (iv) 
assessment of optimal time window; (v) blinded outcome measurement; (vi) assessment of outcome 
at day 1-3; (vii) assessment of outcome at day 7-30 and; (viii) combined measurement of infarct 
volume and functional outcome. 
 
Analysis 
Study data were grouped by protocol prior to analysis: (i) experimental model - permanent or 
transient; (ii) outcome location - total brain, cortex, sub-cortex; (iii) outcome measure - infarct 
volume (mm
3
, %), and CBF (ml.min
-1
.g
-1
, %). Data from each of these groups were analysed as 
forest plots using the Cochrane Collaboration Review Manager (RevMan version 4.1) software. 
Publication bias was assessed using Egger’s asymmetry test (Egger et al. 1997) (Stata function 
‘metabias’). Results are given as standardised mean difference (SMD, reported in units of standard 
deviation), which allows data measured on different scales to be merged, and 95% confidence 
intervals (CI). A random effects model was used since statistical heterogeneity, assessed with a χ
2 
test, was expected in view of the wide range of protocols. Sensitivity analyses were performed to 
look at likely sources of heterogeneity, including NOS inhibitor type (grouped as non-selective 
inhibitors, iNOS inhibitors, nNOS inhibitors), animal species and timing of administration. For the 
latter, articles were divided into those that administered NOS inhibitors before (pre-treated), 0 to 1 
hour after (early treatment) or >1 hour after (late treatment) onset. Meta-regression (STATA, 
version 7.0) was used to analyse the relationship between timing of administration and the effect on 
total infarct volume (SMD) in order to try and determine the size of the therapeutic window. 
Studies were weighted by sample size and only those that administered NOS inhibitors after onset 
of ischaemia were included. Significance was set at P<0.05. 
RESULTS 
 
Design of studies 
Altogether 455 articles were found in the literature search (figure 1). Most of these did not qualify 
for the review, leaving 72 studies (s). Table 1 summarises the characteristics of the included 
articles. The most commonly used agents were non-selective inhibitors such as L-NAME (s=37) 
and L-NNA (s=15). In addition, several compounds were used to target nNOS, including: 7-NI 
(s=9), AR-R 17477 (s=4), BN 80933, PPBP and TRIM. In contrast, there were only two types of 
iNOS inhibitor represented: aminoguanidine (s=12) and 1400W. NOS inhibitors were administered 
to 23 permanent / focal models and to one permanent / global model. More articles assessed the 
effect of NOS inhibition in transient stroke (29 focal, 13 global and 2 using both). In addition, 2 
studies were included which compared a combination of permanent and transient models (Buchan 
et al. 1994; Dawson et al. 1994). Rats were the animal models used in the majority of studies (24 
Sprague Dawley, 21 Wistar, 7 spontaneously hypertensive, 1 Long Evans, 1 Lewis, 1 Fischer). 
Other studies used diverse species, including; rabbits (Anderson and Meyer 1996; Anderson and 
Meyer 2000), cats (Clavier et al. 1994; Nishikawa et al. 1993; Nishikawa et al. 1994), mice 
(Carreau et al. 1994; Ding-Zhou et al. 2002; Goyagi et al. 2001; Gursoy-Ozdemir et al. 2000; Kamii 
et al. 1996; Nowicki et al. 1991; Sugimoto and Iadecola 2002; Zhu et al. 2002), gerbils (Chabrier et 
al. 1999; O'Neill et al. 2000; Spatz et al. 1995), pigs (Greenberg et al. 1995; Hiramatsu et al. 1996; 
Schleien et al. 1998; Segawa et al. 1998), and lambs (Dorrepaal et al. 1997). 
 
Variable methods of drug administration were utilised, e.g. different routes (oral, intra-venous, 
intra-ventricular, intra-arterial, intra-peritoneal), different timings (1
st
 dose ranging from 6 weeks 
before to 48 hours after induction of ischaemia) and different dosage regimens (e.g. total 
administered dose of L-NNA 0.06 – 40.0 mg/kg, L-NAME  0.1mg/kg – 4.2 g/kg, aminoguanidine 
100 – 800 mg/kg, ARL-17477 1.0 – 10.0 mg/kg and 7-NI 0.1 – 100 mg/kg). Study design was more 
consistent for outcome measures. Infarct volumes were assessed by histological staining techniques 
and image analysis of sequential coronal brain sections in nearly all of the studies. An exception to 
this were 3 articles that used serial MRI techniques to monitor lesion progression (Cash et al. 2001; 
Quast et al. 1995; Wei and Quast 1998). Regional CBF after stroke onset was commonly measured 
as percentage (of baseline or control values) using laser doppler flowmetry (Batteur-Parmentier et 
al. 2000; Buchan et al. 1994; Goyagi et al. 2001; Greenberg et al. 1995; Gursoy-Ozdemir et al. 
2000; Hashimoto et al. 1999; Humphreys and Koss 1998; Iadecola et al. 1996; Iadecola et al. 1995; 
Jiang et al. 1999; Prado et al. 1993; Sakashita et al. 1994; Santizo et al. 2000; Sugimura et al. 1998; 
Zhang and Iadecola 1993; Zhao et al. 1999). In addition, one article indirectly assessed total CBF 
using an ultrasonic flow transducer (Dorrepaal et al. 1997). Alternatively, several studies analysed 
CBF as ml.min
-1
.g
-1
 using 
14
C-iodoantipyrine (Ashwal et al. 1994; Stagliano et al. 1997; Wei et al. 
1994), hydrogen clearance (Matsui et al. 1997; Sadoshima et al. 1997; Segawa et al. 1998; Uetsuka 
et al. 2002), radiolabelled microsphere (Clavier et al. 1994; Hiramatsu et al. 1996; Nishikawa et al. 
1993; Nishikawa et al. 1994; Schleien et al. 1998) or umbelliferone fluorescence (Anderson and 
Meyer 1996; Anderson and Meyer 2000) techniques.  
 
The median quality rating for the included articles was 3 points (range 1-6/8). Treatment was 
allocated by randomisation in only 16 articles whilst 26 studies assessed dose response; just 13 
studies assessed the optimal timing of administration. Most studies examined outcome measures 
between days 1-3; only 9 did this blinded to treatment whilst 11 looked at functional outcome as 
well as infarct volume. 
 
Infarct volume and CBF 
Collectively, NOS inhibitors caused a significant reduction in total, cortical and sub-cortical infarct 
volume of magnitude 0.5 to 1.2 standard deviations (table 2). Paradoxically, detrimental effects on 
CBF were observed in the cerebral cortex of permanent stroke models. Most CBF data came from 
studies administering non-selective inhibitors. There was no evidence of publication bias for 
articles reporting the effect of NOS inhibition on total lesion volume in permanent (Egger’s test 
p=0.33), or transient (Egger’s test p=0.65) models. Since heterogeneity was observed in several of 
the analyses, infarct volume and CBF were further examined by type of NOS inhibitor (table 3), in 
different animal models (table 4) and by different timings of administration (table 5). 
 
Type of NOS inhibitor 
Non-selective inhibitors 
In permanent stroke models non-selective inhibitors did not significantly alter infarct volume but 
did reduce cortical CBF (table 3). By contrast, after transient ischaemia non-selective inhibitors 
reduced total infarct volume and did not affect CBF (table 3). 
 
nNOS inhibitors 
nNOS inhibitors significantly reduced infarct volume in both permanent and transient stroke models 
(table 3). At 1 hour of reperfusion there was no overall effect on cortical CBF in transient models. 
However, reduced cortical CBF was seen in one small (n=8) study involving permanent ischaemia. 
 
iNOS inhibitors 
Aminoguanidine and 1400W significantly reduced infarct volume in both permanent and transient 
stroke models. No studies of selective iNOS inhibitors on CBF were identified. 
 
Timing of treatment 
Treatment before stroke onset was effective at reducing infarct volume in transient models (table 4) 
whilst early administration of NOS inhibitors (within 1 hour of onset) was effective in permanent 
stroke. Later treatment after 1 hour of onset had a beneficial effect on infarct volume in both types 
of stroke model. Meta-regression analysis found no evidence of a relationship between total infarct 
volume (SMD) and timing of administration in permanent (p=0.18) or transient (p=0.20) models 
(figure 3).  
 
Animal Model 
Overall, NOS inhibitors appeared to reduce total brain lesion size in agyrencephalic species (table 
5) but not in rabbits or cats. Limited data were available on the effects of NOS inhibitors in higher 
animals. 
DISCUSSION 
We have examined systematically the effects of NOS-inhibitors on infarct size in experimental 
stroke models. Apart from 7 studies (Hamada et al. 1995; Kamii et al. 1996; Kuluz et al. 1993; 
Nakashima et al. 1999; Xu et al. 2000; Yamamoto et al. 1992; Zhang and Iadecola 1993), most of 
the individual articles were either positive or neutral for this outcome. However, when considered 
together there was an overall beneficial effect, such that NOS-inhibitors decreased lesion size by 
about 0.5 to 1.2 standard deviations. Mechanisms that may explain these findings include; reduced 
formation of peroxynitrite and reactive oxygen species (Caldwell et al. 1995; Gumuslu et al. 1997; 
Seif-el-Nasr and Fahim 2001; Solenski and Kwan 2000), inhibition of brain oedema (Peeters-
Scholte et al. 2002; Quast et al. 1995), reduced vascular damage (Ding-Zhou et al. 2002; Gursoy-
Ozdemir et al. 2000), and inhibition of apoptosis and necrosis (Charriaut-Marlangue et al. 1996; 
Peeters-Scholte et al. 2002). Additional work confirms that NOS inhibitors can increase 
hippocampal neuronal survival in experimental stroke (Caldwell et al. 1994; Chabrier et al. 1999; 
Jones et al. 1998; Kohno et al. 1995; Nanri et al. 1998; O'Neill et al. 1996; O'Neill et al. 1997; 
O'Neill et al. 2000) and improve functional outcome (Chabrier et al. 1999; Ding-Zhou et al. 2002; 
Gursoy-Ozdemir et al. 2000; Nagayama et al. 1998; Parmentier et al. 1999). However, not all 
published experimental studies agree with these findings, possibly because of differences in drug 
pharmacology, dosage, route of administration, timing of treatment, animal model and type of 
ischaemia. Some of these factors were examined further in this systematic review. 
 
NOS inhibitor type 
Non-selective inhibitors did not alter infarct volume in permanent ischaemia, whereas the selective 
nNOS and iNOS inhibitors reduced lesion size regardless of experimental model. It is likely that the 
beneficial effects of non-selective inhibitors were limited because they inhibit eNOS to a similar 
degree as nNOS or iNOS. Consequently, they may aggravate brain ischaemia by increasing platelet 
aggregation and white cell activity, raising blood pressure, and by restricting penumbral blood 
supply. Evidence of reduced CBF after administration of non-selective inhibitors to permanent 
stroke models is consistent with this hypothesis. Hence, the non-selective inhibitors are not agents 
of first choice for testing in clinical stroke. 
 
Type of experimental model 
Indirect assessment of the pooled data in table 2 suggests that NOS inhibitors were equally effective 
in transient and permanent ischaemia. However, sub-group analysis revealed that non-selective 
inhibitors did not work in permanent stroke but did in transient stroke (table 3). This discrepancy 
could be attributed to the presence of additional beneficial effects after transient ischaemia, such as 
limitation of reperfusion injury caused by eNOS-derived NO (Gursoy-Ozdemir et al. 2000). 
Alternatively, it could be due to the absence of detrimental effects of non-selective inhibitors in 
transient models. Consistent with this second theory is the observation that non-specific inhibitors 
had no detrimental effects on CBF at 1 hour of reperfusion (table 3).  
 
Timing of treatment 
The administration of 1
st
 dose varied considerably from 6 weeks prior to 24 hours after onset of 
ischaemia. Treatment with NOS-inhibitors was effective prior to onset of transient ischaemia, 
within 1 hour of permanent ischaemia, and even beyond 1 hour of onset in both transient and 
permanent ischaemia models. The neutral findings seen with pre-treatment of permanent models 
and early treatment of transient models probably represents the use of non-selective agents and 
paucity of data rather than lack of response to NOS inhibitors. More important is the confirmation 
that these agents reduce infarct volume even when administered beyond 1 hour after stroke onset. If 
NOS-inhibitors are effective beyond the normal neuroprotective window of 2-4 hours, then it is 
likely that they work through other mechanisms, perhaps enhancing neurogenesis. Also, beneficial 
activity several hours after stroke suggests that the NOS inhibitors might be useful in clinical 
stroke. Unfortunately, meta-regression analysis of timing of administration did not find any 
evidence of a therapeutic window. More experimental studies with delayed administration are 
required to assess when the optimum time window closes. 
 
Animal model 
Significant infarct reductions after either transient or permanent ischaemia were seen in all rat 
strains apart from Fischer rats. Only spontaneously hypertensive rats responded to NOS inhibitors 
in both transient and permanent models. This discrepancy could arise because normotensive strains 
(SDR, WR, Fischer) suffer smaller and more variable infarcts than SHR (Ginsberg and Busto 
1989). In mice, NOS inhibitors worked in permanent but not transient stroke. This inconsistency is 
most likely due to lack of data, although these studies are complex to assess because different 
transgenic mouse strains were used. Unfortunately, lack of data prevents any definitive statements 
about the role of NOS inhibitors in rabbits and cats. More studies need to be performed in 
lissencephalic and/or gyrencephalic species before clinical trials are commenced, as per the STAIR 
recommendations (Stroke Therapy Academic Industry Roundtable (STAIR) 1999). 
 
Limitations 
Although this study has demonstrated an association between administration of NOS inhibitors and 
reduced infarct volume, the findings are limited by several factors. First, there were differences 
between study protocols in terms of animal species, physiological parameters (e.g. blood pressure), 
drug administration (dosage, route), surgical methodology, and duration of ischaemia. 
Unfortunately, it is not possible to judge whether the relationships we observed were independent 
of these factors. In addition, protocol variations can lead to statistical heterogeneity and make the 
analysis less reliable. To take account of this we used a random effects model and performed 
sensitivity analyses to identify sources of heterogeneity. Second, some relevant articles may not 
have been identified for inclusion in the review. Publication bias can contribute to this, either 
through of lack of reporting of neutral or negative studies or through suppression of positive studies 
for commercial reasons, e.g. intellectual property rights. This could mean the benefits of NO on 
infarct volume and CBF have been either over or underestimated. Statistical assessment using 
Egger’s asymmetry test did not suggest the presence of publication bias but the possibility that 
some relevant data was omitted cannot be ruled out. Third, there were several instances when 
numerical data were not readily available and we had to derive these directly from published 
figures. This can be imprecise, although we enlarged graphs and used two authors to extract data. 
Fourth, some NOS inhibitors work though additional neuroprotective mechanisms that do not only 
involve inhibition of NO synthesis. Moreover, some of the ‘selective’ inhibitors only discriminate 
moderately between iNOS and nNOS (Alderton et al. 2001). Unfortunately, it is not possible to 
ascertain whether the relationships we have observed in each sub-group are independent of this. 
Fifth, the technique of extracting multiple pieces of information from single publications has a 
potential to introduce bias into the review since the results would have been generated by the same 
investigators / laboratories. Finally, since the median quality rating of the studies was only 3 out of 
a total of 8, there are likely to be methodological weaknesses in the included studies. Two key areas 
of concern are that studies are not reporting that they randomised animals to active and control 
treatment, and performed outcome assessment blinded to treatment assignment. All studies 
evaluating agents in experimental stroke models should follow published recommendations on 
preclinical drug development (Stroke Therapy Academic Industry Roundtable (STAIR) 1999). 
 
Accepting these limitations, this systematic review brings together data from all published studies 
and suggests that NOS inhibitors, especially if ‘selective’ to nNOS or iNOS, reduce infarct volume 
in experimental stroke. Non-selective inhibitors may be less effective, probably because they 
compromise CBF. Consequently, selective NOS inhibitors are candidate treatments for testing in 
clinical stroke. 
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TABLE 1 
 
Included studies 
 
Drug Studies Species Quality Total N Model P/T Occlusion G/F 1
st
 dose timing (min) route Measures 
         infarct vol CBF 
           
Non specific inhibitors           
L-NAME (Anderson and Meyer 1996) R 3 42 T F -20 i.v.  ml.min
-1
.g
-1
 
  (Anderson and Meyer 2000) R 3 15 P F -30 i.v. % ml.min
-1
.g
-1
 
  (Ashwal et al. 1993) SHR 2 14 T F -60 i.v.  mm
3
  
  (Ashwal et al. 1994) SHR 3 ? T F +0, +120, +150 i.v. mm
3
, % ml.min
-1
.g
-1
, 
% 
 (Ashwal et al. 1995) SHR 3 14 T F -60 i.p. % , mm
3
  
 (Batteur-Parmentier et al. 2000) SDR 3 110 T F +5 i.p. mm
3
 % 
  (Buisson et al. 1992) SDR 2 ? P F +5 i.p.  mm
3
  
  (Buisson et al. 1993) SDR 2 50 P F -30 i.p.  mm
3
  
  (Charriaut-Marlangue et al. 1996) SDR 1 42 T F +5 i.p.  mm
3
, %  
  (Clavier et al. 1994) C 3 24 T G +180 i.v.  ml.min
-1
.g
-1
 
  (Coert et al. 1999) WR 3 92 T F -30 i.v. mm
3
  
  (Dawson et al. 1992a) SDR 3 18 P F -30  s.c mm
3
  
  (Dawson et al. 1994) SDR 3 67 P, T F -30 i.p.  mm
3
  
  (Ding-Zhou et al. 2002) M 4 ? T F +180 i.p.  mm
3
  
  (Greenberg et al. 1995) P 4 20 T G -60 i.v.  ml.min
-1
.g
-1
 
 (Hamada et al. 1995) WR 4 77 P F -20 i.c.v. mm
3
  
 (Hiramatsu et al. 1996) P 2 40 T G -? i.v.  ml.min
-1
.g
-1
 
  (Humphreys and Koss 1998) SDR 3 63 T G -30 i.v.  % 
  (Iuliano et al. 1995) WR 4 78 T F -30 i.v. mm
3
  
  (Kamii et al. 1996) M 2 ? T F +5 i.p. mm
3
  
  (Kuluz et al. 1993) WR 4 24 T F -15 i.v. mm
3
  
  (Margaill et al. 1997) SDR 4 ? T F +5, 180, 360, 540,720 i.p. mm
3
  
  (Nishikawa et al. 1993) C 4 20 P F -30 i.v. % , mm
3
 ml.min
-1
.g
-1
 
  (Nishikawa et al. 1994) C 2 49 T F -60, +45 i.v. % ml.min
-1
.g
-1
 
  (Prado et al. 1993) WR 2 14 T G -5 i.v.  % 
 (Puisieux et al. 2000) WR 2 52 P F -4320 i.p. mm
3
  
  (Quast et al. 1995) SDR 2 36 T F -1 i.v. mm
3
  
 (Schleien et al. 1998) P 3 18 T G -? i.v.  ml.min
-1
.g
-1
 
  (Segawa et al. 1998) P 4 12 T G +90 i.v.  ml.min
-1
.g
-1
 
  (Sercombe et al. 2001) SDR 1 37 P F -20160, -60480 p.o. mm
3
  
 (Stagliano et al. 1997) WR 3 29 P F +5 i.v.  ml.min
-1
.g
-1
 
 (Sugimura et al. 1998) WR 3 18 T G -? ?  % 
 (Uetsuka et al. 2002) WR 3 40 T G -120 i.v.  ml.min
-1
.g
-1
 
  (Wei et al. 1994) LER 2 28 P F +15 i.v.  ml.min
-1
.g
-1
 
  (Wei and Quast 1998) SDR 2 22 T F -1 i.p.  mm
3
  
 (Zhang and Iadecola 1993) SDR 2 31 P F +3 i.a. mm
3
 % 
  (Zhao et al. 1999) WR 2 36 T G -30 i.p.   % 
           
 L-NNA (Buchan et al. 1994) WR, SHR 6 ? T, P G, F -30 , +5 i.p.  mm
3
 % 
 (Carreau et al. 1994) M 3 ? P F +5 i.p.  mm
3
, %  
  (Dorrepaal et al. 1997) L 3 18 T G +35 i.v. .  % 
  (Gursoy-Ozdemir et al. 2000) M 4 65 T F +105 i.p.  mm
3
  
  (Hashimoto et al. 1999) WR 2 ? T F -10 i.p., i.a.. % % 
  (Matsui et al. 1997) SDR 4 148 T F -5, +5 i.p.  mm
3
 ml.min
-1
.g
-1
 
  (Nakashima et al. 1999) WR, FR 1 ? T F +120 i.p., i.v. . mm
3
  
  (Nowicki et al. 1991) M 1 31 P F +5 i.p.  mm
3
  
  (Sadoshima et al. 1997) SHR 2 34 T G +60 i.v.   ml.min
-1
.g
-1
, 
% 
 (Santizo et al. 2000) SDR 2 26 P F -45 i.v.  % 
 (Spatz et al. 1995) MG 2 ? T G -240 i.p.  % 
  (Spinnewyn et al. 1999) SDR 3 88 T F +240 i.v.  mm
3
  
 (Xu et al. 2000) SDR 1 24 P F -30 i.p. mm
3
  
  (Yamamoto et al. 1992) WR 2 37 P F +5 i.v.  mm
3
  
  (Zhang et al. 1996b) WR 3 73 T F +120 i.v.  % % 
           
L-NMMA (Sakashita et al. 1994) WR 1 30 T G -5 i.p.  % 
           
nNOS inhibitors           
           
  7NI (Coert et al. 1999) WR 3 92 T F -60 i.p. mm
3
  
  (Escott et al. 1998) SDR 6 55 T F +5, +90 i.p. %, mm
3
  
  (Goyagi et al. 2001) WR, M 5 115 T F -30  i.p. %  
 (Gursoy-Ozdemir et al. 2000) M 4 65 T F -30, +90 i.p. mm
3
  
  (Humphreys and Koss 1998) SDR 3 63 T G -30 i.v. .  % 
 (Jiang et al. 1999) WR 3 18 T G -20 i.p.  % 
  (Kamii et al. 1996) M 2 ? T F +5 i.p. mm
3
  
 (Uetsuka et al. 2002) WR 3 40 T G -60 i.p.  ml.min
-1
.g
-1
 
  (Yoshida et al. 1994) SDR 3 55 P F +5 i.p. mm
3
  
           
 AR-R 17477 (Harukuni et al. 1999) WR 5 53 P F -30, +60 i.v. . mm
3
  
 (O'Neill et al. 2000) MG, WR 4 ? T F, G 0, +30, +120 i.v. mm
3
  
 (Santizo et al. 2000) SDR 2 26 P F -45 i.v.  % 
  (Zhang et al. 1996b) WR 3 48 T F +120 i.v.  % % 
           
 BN 80933 (Chabrier et al. 1999) SDR, MG 6 ? T F, G +5, 240, 360, 480, 1440 i.v. mm
3
  
           
 PPBP (Goyagi et al. 2001) WR, M 5 115 T F -30 i.p. .i.v. %  
           
 TRIM (Escott et al. 1998) SDR 6 55 T F +5 or 90 i.p. %, mm
3
  
           
           
iNOS inhibitors           
           
1400W (Parmentier et al. 1999) SDR 3 ? T F +1080 s.c. mm
3
  
           
Aminoguanidine (Cash et al. 2001) SDR 3 ? T F +360  i.p. mm
3
  
 (Cockroft et al. 1996) LR 4 ? P F +15, 60, 120, 180 i.p. %  
 (Han et al. 2002) SDR 3 ? T F +0 i.p. %  
 (Iadecola et al. 1995) SHR 2 53 P F +1440 i.p. mm
3
 % 
 (Iadecola et al. 1996) SDR 2 79 T F +360 i.p. mm
3
  
 (Nagayama et al. 1998) SHR 4 60 P F +1440 i.p. mm
3
, %  
 (Sugimoto and Iadecola 2002) M 3 58 P F +1080 i.p. mm
3
  
 (Tsuji et al. 2000) WR 3 31 P G -60 i.p. %  
 (Xu et al. 2000) SDR 1 24 P F -30 i.p. mm
3
  
 (Zhang et al. 1996a) SDR 1 71 T F +1440 i.p. mm
3
, %  
 (Zhang and Iadecola 1998) SHR 3 47 P F +0 i.p. mm
3
  
 (Zhu et al. 2002) M 2 75 T F +360 i.p. %  
 
Abbreviations: Mice (M); Mongolian Gerbil (MG); Piglets (P); Lambs (L); Cats (C); Spontaneously Hypertensive rat (SHR); Sprague-Dawley rat (SDR); Wistar rat (WR); Long-
Evans rat (LER); Lewis Rats (LR); Fischer Rats (FR); Rabbits (R); male (M); female (F); permanent (P); transient (T); global (G); focal (F); intra-venous (i.v.); intra-arterial (i.a.); 
intra-peritoneal (i.p.); infarct volume (infarct vol.); cerebral blood flow (CBF) 
TABLE 2 
 
Effect of NOS inhibitors on lesion volume and cerebral blood flow (SMD, 95% CI) by brain region in permanent and transient ischaemia 
 
Outcome  Permanent   Transient 
 
 
 Total 
 
Cortical Sub-cortical Total Cortical Sub-cortical 
Lesion volume -0.51*  
(-0.82, -0.20) 
S=19, n=532 
 
-1.13*  
(-1.57, -0.70) 
S=15, n=303 
-0.57*  
(-0.92, -0.23) 
S=13, n=318 
-1.01*  
(-1.29, -0.73) 
S=28, n=919 
-0.69*  
(-0.94, -0.43) 
S=12, n=488 
-0.40* 
 (-0.74, -0.06) 
S=11, n=363 
CBF  
No data 
 
-0.80*  
(-1.34, -0.27) 
S=6, n=87 
-0.73  
(-1.83, 0.36) 
S=1, n=14 
 
-0.57 
(-1.26, 0.11) 
S=8, n=120 
-0.22  
(-0.52, 0.07) 
S=15, n=320 
-0.38 
(-1.03, 0.26) 
S=3, n=66 
 
Abbreviations: Standardised mean difference (SMD); cerebral blood flow (CBF); 95% confidence intervals (95% CI); number of studies (S); number 
of animals (n); *p<0.05 
TABLE 3 
 
Effect of selective and non-selective nitric oxide synthase inhibitors on infarct volume and cerebral blood flow (SMD, 95%CI) in stroke models 
 
 Permanent Transient 
Inhibitor Total Volume Cortical CBF Total Volume Cortical CBF 
Non-selective 0.11 
(-0.43, 0.65) 
S=13, n=258 
 
-0.68* 
(-1.17, -0.19)  
S=6, n=83 
-0.90* 
(-1.34, -0.47) 
S=18, n=455 
 
-0.33 
(-0.68, 0.02) 
 S=14, n=266 
iNOS -0.92* 
(-1.16, -0.69) 
S=6, n=256 
 
 
No data 
-1.98* 
(-2.80, -1.15) 
S=6, n=91 
 
 
No data 
nNOS -1.36* 
(-2.05, -0.67) 
S=1, n=30 
-2.62* 
(-4.89, -0.35) 
S=1, n=8 
-0.90* 
(-1.28, -0.54) 
S=7, n=373 
+0.12 
(-0.38, 0.62) 
S=4, n=66 
 
Abbreviations: Inducible nitric oxide synthase (iNOS); neuronal nitric oxide synthase (nNOS); standardised mean difference (SMD); cerebral blood 
flow (CBF); 95% confidence intervals (95% CI); number of studies (S); number of animals (n); *p<0.05 
 TABLE 4 
 
Effect of timing of administration on total infarct volume (SMD, 95%CI) 
 
Model Timing   
 Pre-treatment Early Late 
Permanent 
 
+0.40  
(-0.01, 0.81) 
S=8, n=170 
 
-0.83*  
(-1.25, -0.41) 
 S=8, n=249 
-1.20* 
 (-1.55, -0.86) 
S=4, n=141 
Transient 
 
-1.55*  
(-2.11, -0.99) 
S=9, n=191 
 
-0.16  
(-0.98, 0.67) 
S=3, n=140 
-0.87*  
(-1.24, -0.50) 
S=11, n=454 
 
Abbreviations: Standardised mean difference (SMD); 95% confidence intervals (95% CI); number of studies (S); number of animals (n); *p<0.05 
TABLE 5 
 
Effect of nitric oxide synthase inhibitors by animal model on total infarct volume (SMD, 95%CI) 
 
 
Model Spontaneously 
hypertensive 
rat 
Lewis rat Sprague 
Dawley rat 
Wistar rat Fischer rat Mouse Rabbit Cat 
 
Permanent -0.99* 
(-1.36, -0.61) 
S=3, n=135 
 
-0.89* 
(-1.28, -0.50) 
S=1, n=80 
-0.18 
(-0.74, 0.39) 
S=7, n=152 
+1.05 
(-0.05, 2.15) 
S=3, n=55 
 
No data 
-1.64* 
(-2.22, -1.07) 
S=2, n=68 
+1.31* 
(0.20, 2.42) 
S=1, n=15 
+0.20 
(-0.68, 1.08) 
S=1, n=20 
 
Transient -2.10* 
(-2.81, -1.39) 
S=1, n=51 
 
No Data 
-1.15* 
(-1.56, -0.74) 
S=9, n=239 
-0.61* 
(-1.10, -0.12) 
S=5, n=236 
+0.69 
(-0.06, 1.43) 
S=1, n=34 
 
-0.91 
(-1.90, 0.08) 
S=3, n=156 
 -0.05 
(-0.81, 0.71) 
S=1, n=30 
 
 
 
Abbreviations: Standardised mean difference (SMD); 95% confidence intervals (95% CI); number of studies (S); 
FIGURE 1 
 
Search process showing reasons for exclusion of studies 
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FIGURE 2a 
 
Total lesion volume by different NOS inhibitor types for permanent models of ischaemia 
 
 
FIGURE 2b 
 
Cortical CBF by different NOS inhibitor types for transient models of ischaemia 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effect of delay until first dose (minutes) on total infarct volume (SMD) in transient 
ischaemia. Size of circle proportional to size of study. 
 References 
 
Alderton WK, Cooper CE, Knowles RG. (2001) Nitric oxide synthases: structure, function and 
inhibition. Biochem J 357:593-615 
Anderson RE, Meyer FB. (1996) Nitric oxide synthase inhibition by L-NAME during repetitive 
focal cerebral ischemia in rabbits. Am J Physiol 271:H588-594 
Anderson RE, Meyer FB. (2000) Is intracellular brain pH a dependent factor in NOS inhibition 
during focal cerebral ischemia? Brain Res 856:220-226 
Ashwal S, Cole DJ, Osborne S, Osborne TN, Pearce WJ. (1995) L-NAME reduces infarct volume 
in a filament model of transient middle cerebral artery occlusion in the rat pup. Pediatr Res 
38:652-656 
Ashwal S, Cole DJ, Osborne TN, Pearce WJ. (1993) Low dose L-NAME reduces infarct volume in 
the rat MCAO/reperfusion model. J Neurosurg Anesthesiol 5:241-249 
Ashwal S, Cole DJ, Osborne TN, Pearce WJ. (1994) Dual effects of L-NAME during transient 
focal cerebral ischemia in spontaneously hypertensive rats. Am J Physiol 267:H276-284 
Batteur-Parmentier S, Margaill I, Plotkine M. (2000) Modulation by nitric oxide of cerebral 
neutrophil accumulation after transient focal ischemia in rats. J Cereb Blood Flow Metab 
20:812-819 
Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. (1990) Apparent hydroxyl radical 
production by peroxynitrite: implications for endothelial injury from nitric oxide and 
superoxide. Proc Natl Acad Sci U S A 87:1620-1624 
Buchan AM, Gertler SZ, Huang ZG, Li H, Chaundy KE, Xue D. (1994) Failure to prevent selective 
CA1 neuronal death and reduce cortical infarction following cerebral ischemia with 
inhibition of nitric oxide synthase. Neuroscience 61:1-11 
Buisson A, Margaill I, Callebert J, Plotkine M, Boulu RG. (1993) Mechanisms involved in the 
neuroprotective activity of a nitric oxide synthase inhibitor during focal cerebral ischemia. J 
Neurochem 61:690-696 
Buisson A, Plotkine M, Boulu RG. (1992) The neuroprotective effect of a nitric oxide inhibitor in a 
rat model of focal cerebral ischaemia. Br J Pharmacol 106:766-767 
Caldwell M, O'Neill M, Earley B, Kelly JP, Leonard BE. (1995) NG-nitro-L-arginine methyl ester 
protects against lipid peroxidation in the gerbil following cerebral ischaemia. Eur J 
Pharmacol 285:203-206 
Caldwell M, O'Neill M, Earley B, Leonard B. (1994) NG-Nitro-L-arginine protects against 
ischaemia-induced increases in nitric oxide and hippocampal neuro-degeneration in the 
gerbil. Eur J Pharmacol 260:191-200 
Carreau A, Duval D, Poignet H, Scatton B, Vige X, Nowicki JP. (1994) Neuroprotective efficacy of 
N omega-nitro-L-arginine after focal cerebral ischemia in the mouse and inhibition of 
cortical nitric oxide synthase. Eur J Pharmacol 256:241-249 
Cash D, Beech JS, Rayne RC, Bath PMW, Meldrum BS, Williams SCR. (2001) Neuroprotective 
effect of aminoguanidine on transient focal ischaemia in the rat brain. Brain Research 
905:91-103 
Chabrier PE, Auguet M, Spinnewyn B, Auvin S, Cornet S, Demerle-Pallardy C, Guilmard-Favre C, 
Marin JG, Pignol B, Gillard-Roubert V, Roussillot-Charnet C, Schulz J, Viossat I, Bigg D, 
Moncada S. (1999) BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid 
peroxidation: a promising neuroprotective strategy. Proc Natl Acad Sci U S A 96:10824-
10829 
Charriaut-Marlangue C, Margaill I, Borrega F, Plotkine M, Ben-Ari Y. (1996) NG-nitro-L-arginine 
methyl ester reduces necrotic but not apoptotic cell death induced by reversible focal 
ischemia in rat. Eur J Pharmacol 310:137-140 
Clavier N, Kirsch JR, Hurn PD, Traystman RJ. (1994) Cerebral blood flow is reduced by N omega-
nitro-L-arginine methyl ester during delayed hypoperfusion in cats. Am J Physiol 267:H174-
181 
Cockroft KM, Meistrell M, 3rd, Zimmerman GA, Risucci D, Bloom O, Cerami A, Tracey KJ. 
(1996) Cerebroprotective effects of aminoguanidine in a rodent model of stroke. Stroke 
27:1393-1398 
Coert BA, Anderson RE, Meyer FB. (1999) A comparative study of the effects of two nitric oxide 
synthase inhibitors and two nitric oxide donors on temporary focal cerebral ischemia in the 
Wistar rat. J Neurosurg 90:332-338 
Dawson DA, Graham DI, McCulloch J, Macrae IM. (1994) Anti-ischaemic efficacy of a nitric 
oxide synthase inhibitor and a N-methyl-D-aspartate receptor antagonist in models of 
transient and permanent focal cerebral ischaemia. Br J Pharmacol 113:247-253 
Dawson DA, Kusumoto K, Graham DI, McCulloch J, Macrae IM. (1992a) Inhibition of nitric oxide 
synthesis does not reduce infarct volume in a rat model of focal cerebral ischaemia. 
Neurosci Lett 142:151-154 
Dawson TM, Dawson VL, Snyder SH. (1992b) A novel neuronal messenger molecule in brain: the 
free radical, nitric oxide. Ann.Neurol. 32:297-311 
Dimmeler S, Brune B. (1993) Nitric oxide preferentially stimulates auto-ADP-ribosylation of 
glyceraldehyde-3-phosphate dehydrogenase compared to alcohol or lactate dehydrogenase. 
FEBS Lett 315:21-24 
Ding-Zhou L, Marchand-Verrecchia C, Croci N, Plotkine M, Margaill I. (2002) L-NAME reduces 
infarction, neurological deficit and blood-brain barrier disruption following cerebral 
ischemia in mice. Eur J Pharmacol 457:137-146 
Dorrepaal CA, Shadid M, Steendijk P, Van der Velde ET, Van de Bor M, Baan J, Van Bel F. 
(1997) Effect of post-hypoxic-ischemic inhibition of nitric oxide synthesis on cerebral blood 
flow, metabolism and electrocortical brain activity in newborn lambs. Biol Neonate 72:216-
226 
Egger M, Davey Smith G, Schneider M, Minder C. (1997) Bias in meta-analysis detected by a 
simple, graphical test. BMJ 315:629-634 
Escott KJ, Beech JS, Haga KK, Williams SCR, Meldrum BS, Bath PMW. (1998) Cerebroprotective 
effect of the nitric oxide synthase inhibitors, 1-(2-trifluoromethylphenyl) imidazole (TRIM) 
and 7-nitro indazole, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow 
Metab 18:281-287 
Garthwaite J. (1991) Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends 
Neurosci 14:60-67 
Garvey EP, Oplinger JA, Tanoury GJ, Sherman PA, Fowler M, Marshall S, Harmon MF, Paith JE, 
Furfine ES. (1994) Potent and selective inhibition of human nitric oxide synthases. 
Inhibition by non-amino acid isothioureas. J Biol Chem 269:26669-26676 
Ginsberg MD, Busto R. (1989) Rodent models of cerebral ischemia. Stroke 20:1627-1642 
Goyagi T, Goto S, Bhardwaj A, Dawson VL, Hurn PD, Kirsch JR. (2001) Neuroprotective effect of 
sigma(1)-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is linked to reduced 
neuronal nitric oxide production. Stroke 32:1613-1620 
Greenberg RS, Helfaer MA, Kirsch JR, Traystman RJ. (1995) Effect of nitric oxide synthase 
inhibition on postischemic cerebral hyperemia. Am J Physiol 269:H341-347 
Gumuslu S, Serteser M, Ozben T, Balkan S, Balkan E. (1997) Inhibitory role of N omega-nitro-L-
arginine methyl ester (L-NAME), a potent nitric oxide synthase inhibitor, on brain 
malondialdehyde and conjugated diene levels during focal cerebral ischemia in rats. Clin 
Chim Acta 267:213-223 
Gursoy-Ozdemir Y, Bolay H, Saribas O, Dalkara T. (2000) Role of endothelial nitric oxide 
generation and peroxynitrite formation in reperfusion injury after focal cerebral ischemia. 
Stroke 31:1974-1980; discussion 1981 
Hamada J, Greenberg JH, Croul S, Dawson TM, Reivich M. (1995) Effects of central inhibition of 
nitric oxide synthase on focal cerebral ischemia in rats. J Cereb Blood Flow Metab 15:779-
786 
Han HS, Qiao Y, Karabiyikoglu M, Giffard RG, Yenari MA. (2002) Influence of mild hypothermia 
on inducible nitric oxide synthase expression and reactive nitrogen production in 
experimental stroke and inflammation. J Neurosci 22:3921-3928 
Handy RL, Wallace P, Gaffen ZA, Whitehead KJ, Moore PK. (1995) The antinociceptive effect of 
1-(2-trifluoromethylphenyl) imidazole (TRIM), a potent inhibitor of neuronal nitric oxide 
synthase in vitro, in the mouse. Br J Pharmacol 116:2349-2350 
Harukuni I, Traystman RJ, Kirsch JR. (1999) Effect of AR-R 17477, a potent neuronal nitric oxide 
synthase inhibitor, on infarction volume resulting from permanent focal ischemia in rats. 
Crit Care Med 27:2508-2511 
Hashimoto H, Ohta S, Utsunomiya H, Kumon Y, Sakaki S, Matsuda S, Sakanaka M. (1999) 
Changes in guanylate cyclase activity in arteriolar smooth muscle cells and hemodynamics 
after ischemia-reperfusion in rats. Acta Neuropathol (Berl) 98:603-613 
Hiramatsu T, Jonas RA, Miura T, duPlessis A, Tanji M, Forbess JM, Holtzman D. (1996) Cerebral 
metabolic recovery from deep hypothermic circulatory arrest after treatment with arginine 
and nitro-arginine methyl ester. J Thorac Cardiovasc Surg 112:698-707 
Horn J, deHaan R, Vermeulen M, Luiten PGM, Limburg M, 2045. (2001) Nimodipine in animal 
model experiments of focal cerebral ischemia. Stroke 32:2433-2438 
Huang Z, Huang PL, Ma J, Meng W, Ayata C, Fishman MC, Moskowitz MA. (1996) Enlarged 
infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-
arginine. Journal of Cerebral Blood Flow and Metabolism 16:981-987 
Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA. (1994) Effects of 
cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 265:1883-
1885 
Humphreys SA, Koss MC. (1998) Role of nitric oxide in post-ischemic cerebral hyperemia in 
anesthetized rats. Eur J Pharmacol 347:223-229 
Iadecola C, Pelligrino DA, Moskowitz MA, Lassen NA. (1994) Nitric oxide synthase inhibition and 
cerebrovascular regulation. J Cereb Blood Flow Metab 14:175-192 
Iadecola C, Zhang F, Casey R, Clark HB, Ross ME. (1996) Inducible nitric oxide synthase gene 
expression in vascular cells after transient focal cerebral ischemia. Stroke 27:1373-1380 
Iadecola C, Zhang F, Xu X. (1995) Inhibition of inducible nitric oxide synthase ameliorates 
cerebral ischemic damage. Am J Physiol 268:R286-292 
Iuliano BA, Anderson RE, Meyer FB. (1995) Effect of intermittent reperfusion and nitric oxide 
synthase inhibition on infarct volume during reversible focal cerebral ischemia. J Neurosurg 
83:491-495 
Jiang MH, Kaku T, Hada J, Hayashi Y. (1999) 7-Nitroindazole reduces nitric oxide concentration in 
rat hippocampus after transient forebrain ischemia. Eur J Pharmacol 380:117-121 
Jones PA, Smith RA, Stone TW. (1998) Nitric oxide synthase inhibitors L-NAME and 7-
nitroindazole protect rat hippocampus against kainate-induced excitotoxicity. Neurosci Lett 
249:75-78 
Kamii H, Mikawa S, Murakami K, Kinouchi H, Yoshimoto T, Reola L, Carlson E, Epstein CJ, 
Chan PH. (1996) Effects of nitric oxide synthase inhibition on brain infarction in SOD-1-
transgenic mice following transient focal cerebral ischemia. J Cereb Blood Flow Metab 
16:1153-1157 
Kohno K, Ohta S, Furuta S, Kumon Y, Sakaki S. (1995) Intraventricular administration of nitric 
oxide synthase inhibitors prevents delayed neuronal death in gerbil hippocampal CA1 
neurons. Neurosci Lett 199:65-68 
Kuluz JW, Prado RJ, Dietrich WD, Schleien CL, Watson BD. (1993) The effect of nitric oxide 
synthase inhibition on infarct volume after reversible focal cerebral ischemia in conscious 
rats. Stroke 24:2023-2029 
Margaill I, Allix M, Boulu RG, Plotkine M. (1997) Dose- and time-dependence of L-NAME 
neuroprotection in transient focal cerebral ischaemia in rats. Br J Pharmacol 120:160-163 
Matsui T, Nagafuji T, Mori T, Asano T. (1997) N omega-nitro-L-arginine attenuates early ischemic 
neuronal damage of prolonged focal cerebral ischemia and recirculation in rats. Neurol Res 
19:192-203 
Montague PR, Gancayco CD, Winn MJ, Marchase RB, Friedlander MJ. (1994) Role of NO 
production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science 
263:973-977 
Nagayama M, Zhang F, Iadecola C. (1998) Delayed treatment with aminoguanidine decreases focal 
cerebral ischemic damage and enhances neurologic recovery in rats. J Cereb Blood Flow 
Metab 18:1107-1113 
Nakashima M, Niwa M, Iwai T, Uematsu T. (1999) Involvement of free radicals in cerebral 
vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat. 
Free Radic Biol Med 26:722-729 
Nanri K, Montecot C, Springhetti V, Seylaz J, Pinard E. (1998) The selective inhibitor of neuronal 
nitric oxide synthase, 7-nitroindazole, reduces the delayed neuronal damage due to forebrain 
ischemia in rats. Stroke 29:1248-1253; discussion 1253-1244 
Nathan C. (1992) Nitric oxide as a secretory product of mammalian cells. Faseb J 6:3051-3064 
Nishikawa T, Kirsch JR, Koehler RC, Bredt DS, Snyder SH, Traystman RJ. (1993) Effect of nitric 
oxide synthase inhibition on cerebral blood flow and injury volume during focal ischemia in 
cats. Stroke 24:1717-1724 
Nishikawa T, Kirsch JR, Koehler RC, Miyabe M, Traystman RJ. (1994) Nitric oxide synthase 
inhibition reduces caudate injury following transient focal ischemia in cats. Stroke 25:877-
885 
Nowicki JP, Duval D, Poignet H, Scatton B. (1991) Nitric oxide mediates neuronal death after focal 
cerebral ischemia in the mouse. Eur J Pharmacol 204:339-340 
O'Neill MJ, Hicks C, Ward M. (1996) Neuroprotective effects of 7-nitroindazole in the gerbil 
model of global cerebral ischaemia. Eur J Pharmacol 310:115-122 
O'Neill MJ, Hicks C, Ward M, Panetta JA. (1997) Neuroprotective effects of the antioxidant 
LY231617 and NO synthase inhibitors in global cerebral ischaemia. Brain Res 760:170-178 
O'Neill MJ, Murray TK, McCarty DR, Hicks CA, Dell CP, Patrick KE, Ward MA, Osborne DJ, 
Wiernicki TR, Roman CR, Lodge D, Fleisch JH, Singh J. (2000) ARL 17477, a selective 
nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and 
focal cerebral ischaemia. Brain Res 871:234-244 
Parmentier S, Bohme GA, Lerouet D, Damour D, Stutzmann JM, Margaill I, Plotkine M. (1999) 
Selective inhibition of inducible nitric oxide synthase prevents ischaemic brain injury. Br J 
Pharmacol 127:546-552 
Peeters-Scholte C, Koster J, Veldhuis W, van den Tweel E, Zhu C, Kops N, Blomgren K, Bar D, 
van Buul-Offers S, Hagberg H, Nicolay K, van Bel F, Groenendaal F. (2002) 
Neuroprotection by selective nitric oxide synthase inhibition at 24 hours after perinatal 
hypoxia-ischemia. Stroke 33:2304-2310 
Prado R, Watson BD, Wester P. (1993) Effects of nitric oxide synthase inhibition on cerebral blood 
flow following bilateral carotid artery occlusion and recirculation in the rat. J Cereb Blood 
Flow Metab 13:720-723 
Puisieux F, Deplanque D, Pu Q, Souil E, Bastide M, Bordet R. (2000) Differential role of nitric 
oxide pathway and heat shock protein in preconditioning and lipopolysaccharide-induced 
brain ischemic tolerance. Eur J Pharmacol 389:71-78 
Quast MJ, Wei J, Huang NC. (1995) Nitric oxide synthase inhibitor NG-nitro-L-arginine methyl 
ester decreases ischemic damage in reversible focal cerebral ischemia in hyperglycemic rats. 
Brain Res 677:204-212 
Radi R, Beckman JS, Bush KM, Freeman BA. (1991) Peroxynitrite-induced membrane lipid 
peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 
288:481-487 
Reif DW, McCarthy DJ, Cregan E, Macdonald JE. (2000) Discovery and development of neuronal 
nitric oxide synthase inhibitors. Free Radic Biol Med 28:1470-1477 
Sadoshima S, Nagao T, Okada Y, Fujii K, Ibayashi S, Fujishima M. (1997) L-arginine ameliorates 
recirculation and metabolic derangement in brain ischemia in hypertensive rats. Brain Res 
744:246-252 
Sakashita N, Ando Y, Yonehara T, Tanaka Y, Sato K, Uchino M, Ando M. (1994) Role of 
superoxide dismutase and nitric oxide on the interaction between brain and systemic 
circulation during brain ischemia. Biochim Biophys Acta 1227:67-73 
Santizo R, Baughman VL, Pelligrino DA. (2000) Relative contributions from neuronal and 
endothelial nitric oxide synthases to regional cerebral blood flow changes during forebrain 
ischemia in rats. Neuroreport 11:1549-1553 
Schleien CL, Kuluz JW, Gelman B. (1998) Hemodynamic effects of nitric oxide synthase inhibition 
before and after cardiac arrest in infant piglets. Am J Physiol 274:H1378-1385 
Segawa D, Hatori N, Yoshizu H, Uriuda Y, Shimizu M, Tanaka S. (1998) The effect of nitric oxide 
synthase inhibitor on reperfusion injury of the brain under hypothermic circulatory arrest. J 
Thorac Cardiovasc Surg 115:925-930 
Seif-el-Nasr M, Fahim AT. (2001) Antioxidant effect of N omega-nitro-L-arginine methyl ester (L-
NAME) on global cerebral ischemia in a rat model. Arzneimittelforschung 51:628-632 
Sercombe R, Issertial O, Seylaz J, Pinard E. (2001) Effects of chronic L-NAME treatment on rat 
focal cerebral ischemia and cerebral vasoreactivity. Life Sci 69:2203-2216 
Solenski NJ, Kwan A. (2000) Attenuation of free radical generation during reversible focal cerebral 
ischemia with the nitric oxide inhibitor, L-NAME (L-N(G)-nitro-L-arginine methyl ester). 
Brain Res 862:262-265 
Sorkin LS. (1993) NMDA evokes an L-NAME sensitive spinal release of glutamate and citrulline. 
Neuroreport 4:479-482 
Spatz M, Stanimirovic D, Strasser A, McCarron RM. (1995) Nitro-L-arginine augments the 
endothelin-1 content of cerebrospinal fluid induced by cerebral ischemia. Brain Res 684:99-
102 
Spinnewyn B, Cornet S, Auguet M, Chabrier PE. (1999) Synergistic protective effects of 
antioxidant and nitric oxide synthase inhibitor in transient focal ischemia. J Cereb Blood 
Flow Metab 19:139-143 
Stagliano NE, Zhao W, Prado R, Dewanjee MK, Ginsberg MD, Dietrich WD. (1997) The effect of 
nitric oxide synthase inhibition on acute platelet accumulation and hemodynamic depression 
in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 17:1182-1190 
Stroke Therapy Academic Industry Roundtable (STAIR). (1999) Recommendations for standards 
regarding preclinical neuroprotective and restorative drug development. Stroke 30:2752-
2758 
Sugimoto K, Iadecola C. (2002) Effects of aminoguanidine on cerebral ischemia in mice: 
comparison between mice with and without inducible nitric oxide synthase gene. Neurosci 
Lett 331:25-28 
Sugimura T, Sako K, Tohyama Y, Yonemasu Y. (1998) Consecutive in vivo measurement of nitric 
oxide in transient forebrain ischemic rat under normothermia and hypothermia. Brain Res 
808:313-316 
Tsuji M, Higuchi Y, Shiraishi K, Kume T, Akaike A, Hattori H. (2000) Protective effect of 
aminoguanidine on hypoxic-ischemic brain damage and temporal profile of brain nitric 
oxide in neonatal rat. Pediatr Res 47:79-83 
Uetsuka S, Fujisawa H, Yasuda H, Shima H, Suzuki M. (2002) Severe cerebral blood flow 
reduction inhibits nitric oxide synthesis. J Neurotrauma 19:1105-1116 
Wei HM, Chi OZ, Liu X, Sinha AK, Weiss HR. (1994) Nitric oxide synthase inhibition alters 
cerebral blood flow and oxygen balance in focal cerebral ischemia in rats. Stroke 25:445-
449; discussion 449-450 
Wei J, Quast MJ. (1998) Effect of nitric oxide synthase inhibitor on a hyperglycemic rat model of 
reversible focal ischemia: detection of excitatory amino acids release and hydroxyl radical 
formation. Brain Res 791:146-156 
Welch G, Loscalzo J. (1994) Nitric oxide and the cardiovascular system. J Card Surg 9:361-371 
Willmot MR, Bath PMW. (2003) The potential of nitric oxide therapeutics in stroke. Expert 
Opinion Investigational Drugs 12:455-470 
Xu SJ, Zhang JX, Li Lf, Du XL. (2000) The effects of nitric oxide synthase inhibitors on the early 
stage of focal cerebral ischaemic injury in rats. Chinese Pharm Bull 16:645-647 
Yamamoto S, Golanov EV, Berger SB, Reis DJ. (1992) Inhibition of nitric oxide synthesis 
increases focal ischemic infarction in rat. J Cereb Blood Flow Metab 12:717-726 
Yoshida T, Limmroth V, Irikura K, Moskowitz MA. (1994) The NOS inhibitor, 7-nitroindazole, 
decreases focal infarct volume but not the response to topical acetylcholine in pial vessels. J 
Cereb Blood Flow Metab 14:924-929 
Young RJ, Beams RM, Carter K, Clark HA, Coe DM, Chambers CL, Davies PI, Dawson J, 
Drysdale MJ, Franzman KW, French C, Hodgson ST, Hodson HF, Kleanthous S, Rider P, 
Sanders D, Sawyer DA, Scott KJ, Shearer BG, Stocker R, Smith S, Tackley MC, Knowles 
RG. (2000) Inhibition of inducible nitric oxide synthase by acetamidine derivatives of 
hetero-substituted lysine and homolysine. Bioorg Med Chem Lett 10:597-600 
Zhang F, Casey RM, Ross ME, Iadecola C. (1996a) Aminoguanidine ameliorates and L-arginine 
worsens brain damage from intraluminal middle cerebral artery occlusion. Stroke 27:317-
323 
Zhang F, Iadecola C. (1993) Nitroprusside improves blood flow and reduces brain damage after 
focal ischemia. Neuroreport 4:559-562 
Zhang F, Iadecola C. (1998) Temporal characteristics of the protective effect of aminoguanidine on 
cerebral ischemic damage. Brain Res 802:104-110 
Zhang ZG, Reif D, Macdonald J, Tang WX, Kamp DK, Gentile RJ, Shakespeare WC, Murray RJ, 
Chopp M. (1996b) ARL 17477, a potent and selective neuronal NOS inhibitor decreases 
infarct volume after transient middle cerebral artery occlusion in rats. J Cereb Blood Flow 
Metab 16:599-604 
Zhao H, Asai S, Ishikawa K. (1999) Neither L-NAME nor L-arginine changes extracellular 
glutamate elevation and anoxic depolarization during global ischemia and reperfusion in rat. 
Neuroreport 10:313-318 
Zhao X, Haensel C, Araki E, Ross ME, Iadecola C. (2000) Gene-dosing effect and persistence of 
reduction in ischemic brain injury in mice lacking inducible nitric oxide synthase. Brain Res 
872:215-218 
Zhu DY, Deng Q, Yao HH, Wang DC, Deng Y, Liu GQ. (2002) Inducible nitric oxide synthase 
expression in the ischemic core and penumbra after transient focal cerebral ischemia in 
mice. Life Sci 71:1985-1996 
 
